Prosecution Insights
Last updated: November 04, 2026
Application No. 18/702,413

METHOD FOR PREPARING RENAL PODOCYTES BY DISCONTINUOUS DIFFERENTIATION

Final Rejection §103§112
Filed
Apr 18, 2024
Priority
Feb 21, 2022 — CN 202210155136.4 +1 more
Examiner
MIANO, JOSEPH PAUL
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guangzhou Asia Kidney Rebuilding Medical Technology Ltd.
OA Round
2 (Final)
36%
Grant Probability
At Risk
3-4
OA Rounds
1y 8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allowance Rate
40 granted / 112 resolved
-24.3% vs TC avg
Strong +63% interview lift
Without
With
+63.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
59 currently pending
Career history
182
Total Applications
across all art units

Statute-Specific Performance

§101
4.7%
-35.3% vs TC avg
§103
46.3%
+6.3% vs TC avg
§102
13.6%
-26.4% vs TC avg
§112
22.6%
-17.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 112 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-4, 6-9 and 11-16 are pending. Claims 1-2, 7-9, 12, and 14 are newly amended. Claims 1-4, 6-9 and 11-16 have been examined on their merits. Withdrawn Objections & Rejections The objections and rejections presented herein represent the full set of objections and rejections currently pending in the application. Any objections or rejections not specifically reiterated are hereby withdrawn. The rejection of claims 1-4, 6-7 and 11 under 35 U.S.C. 103 as being unpatentable over Ingber et al. (WO2016085765A1, on IDS 04/18/2024) in view of Ciampi et al. (Stem Cell Research, 2016, on IDS 04/18/2024) is withdrawn due to amendment of the claims and Applicant’s persuasive arguments. The rejection of claim 5 under 35 U.S.C. 103 as being unpatentable over Ingber et al. (WO2016085765A1, on IDS 04/18/2024) in view of Ciampi et al. (Stem Cell Research, 2016, on IDS 04/18/2024) as applied to claim 1 above, and further in view of Morizane et al. (Nat Protoc, 2017) is withdrawn due to amendment of the claims and Applicant’s persuasive arguments. The rejection of claims 9 and 14-16 under 35 U.S.C. 103 as being unpatentable over Ingber et al. (WO2016085765A1, on IDS 04/18/2024) in view of Ciampi et al. (Stem Cell Research, 2016, on IDS 04/18/2024) and Qian et al. (US20190055520A1, on IDS 04/18/2024) is withdrawn due to amendment of the claims and Applicant’s persuasive arguments. The rejections of claims 8 and 12-13 under 35 U.S.C. 103 as being unpatentable over Ingber et al. (WO2016085765A1, on IDS 04/18/2024) in view of Ciampi et al. (Stem Cell Research, 2016, on IDS 04/18/2024) are maintained as discussed below. Claim Objections Claims 1, 7, and 9 are objected to for the following informalities: these claims as amended all recite “roswell park memorial institute.” However, this is a proper noun and should be capitalized. “Roswell Park Memorial Institute” would be ameliorative. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-4, 6-7, 9, 11, and 14-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Independent claim 1 as newly amended specifically requires in step S1 a medium that contains “non-essential amino acids, sodium pyruvate and glutathione” and is explicitly free of “BMP, activin A . . . and HEPES.” Independent claim 9 as newly amended requires these same limitations. These limitations are new matter (see MPEP 2163.06 notes that when new matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112(a), pre-AIA first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981)). Although Applicant asserts that no new matter has been added (see Remarks 08/31/2026, p5-6), Applicant does not identify where in the disclosure support for these amendments is found. Additionally, a review of the specification, drawings, and claims as originally filed did not find a basis, whether a positive or negative recitation, for any of non-essential amino acids, sodium pyruvate, glutathione, activin A, or HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). Therefore, the disclosure lacks express, implicit, or inherent disclosure of these amendments (see MPEP 2163(B). Regarding the negative limitation wherein the medium does not contain “BMP”, while the disclosure describes the positive recitation of a medium that comprises BMP7 in S2, not only is the amended negative limitation in a different step (instead, S1), but BMP7 is a specific species of molecule, while BMP is a broad genus of molecules. Therefore, the application lacks disclosure for disallowing the broad genus of BMP molecules. Claims 2-4, 6-7, and 11 are rejected under 35 USC 112(a) for their dependence on claim 1. Claims 14-16 are rejected under 35 USC 112(a) for their dependence on claim 9. Claim Rejections - 35 USC § 103 - maintained In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 8 and 12-13 are rejected under 35 U.S.C. 103 as being unpatentable over Ingber et al. (WO2016085765A1, on IDS 04/18/2024) in view of Ciampi et al. (Stem Cell Research, 2016, on IDS 04/18/2024). In regards to claim 8, Ingber teaches methods for the generation of podocytes (Claims 1 and 6). As taught by Ingber these cells ultimately derive from PSCs, and therefore must necessarily pass through a nephron progenitor intermediate cell stage before final differentiation to podocytes. Ingber teaches that this method comprises culturing intermediates in differentiation medium comprising “retinoic acid” (claims 1, 6-10; paragraph [0032]), which Ingber explicitly states refers to derivatives including retinol (vitamin A) specifically (paragraph [00102]). Ingber also teaches that the differentiation medium can comprise L-glutamine, including Glutamax specifically (stabilized L-glutamine) (paragraphs [00146, 00264]). Ingber does not explicitly teach that the medium comprises vitamin D3. Furthermore, the medium is serum-free (claim claims 1 and 6). However, podocyte maturation media comprising vitamin D3 and fetal bovine serum (FBS) were known in the art prior to the effective filing date. Specifically, Ciampi teaches a three-stage method of differentiating PSCs to podocytes (Title, Abstract, p130, 133). In the third stage, Ciampi teaches that that nephron progenitor cells specifically are cultured in media comprising not only FBS and vitamin D3 but also retinoic acid (as above, vitamin A would be an obvious substitution) and Glutamax (2.2. Human iPSC differentiation into podocytes, p131; 3.2. Specification of hiPSC-derived nephron progenitor cells into podocytes, p134). A person of ordinary skill in the art would have been motivated to culture nephron progenitor cells in a media comprising vitamin D3 and FBS because Ciampi teaches that this medium it is known in the art that this medium can successfully differentiate renal progenitors to podocytes (3.2. Specification of hiPSC-derived nephron progenitor cells into podocytes (p134). In regards to FBS specifically, while Ingber uses serum-free conditions, a person of ordinary skill in the art would have been motivated to modify the conditions to serum-containing, depending on the availability of reagents or in order to reduce the costs of serum replacement. Furthermore, because both Ingber and Ciampi are directed to similar methods of differentiating PSCs to podocytes and because Ciampi explicitly teaches that nephron progenitors may differentiate to podocytes in media comprising vitamin D3 and FBS, a person of ordinary skill in the arts could have modified the method of Ingber and added vitamin D3 and substituted FBS with predictable results and a reasonable expectation of success. Ingber teaches that podocytes specifically can be induced or differentiated in a medium comprising DMEM/F12 (paragraphs [0084, 00247]). Furthermore, Ciampi demonstrates that nephron progenitor cells are differentiated to podocytes in DMEM/F12 (2.2. Human iPSC differentiation into podocytes, p131). In regards to claim 12, in regards to the concentrations, in regards to vitamin A, as above, Ingber teaches that “retinoic acid” (i.e., vitamin A) can have a concentration of about 0.01 μΜ to about 1 μΜ (claim 25; paragraph [0031]), which overlaps with the claimed range. While, as above, Ingber teaches that the medium can comprise Glutamax, Ingber is silent as to the amount. However, again, a person of ordinary skill in the art could have arrive at a concentration of 0.1% - 10% by routine optimization, and the disclosure does not point to a criticality in this amount. In the instant case because Ciampi teaches that renal cells can be cultured in 1% L-glutamine (which as above, Glutamax is the commercial formulation of) (2.10. Chimeric organoids culture, p132), not only could a person of ordinary skill in the art arrived at the claimed concentration by routine optimization with predictable results and a reasonable expectation of success, but it would have also been predictably obvious to do so. In regards to the concentrations of vitamin D3 and FBS, Ciampi teaches that these can be 10% FBS and 100 nM vitamin D3 (2.2. Human iPSC differentiation into podocytes, p131; 3.2. Specification of hiPSC-derived nephron progenitor cells into podocytes, p134) which overlaps with the claimed ranges. It would have been predictably obvious to use these concentrations because Ciampi demonstrates that they are suitable for final differentiation of podocytes. In regards to claim 13, in regards to the timings, Ingber teaches that PSCs can be induced for at least about 3 days (72 hours) (claim 1, including also the broad range of about 12 hours to about 10 days, paragraph [0019]), which overlaps with the claimed range. Therefore, the combined teachings of Ingber and Ciampi renders the invention unpatentable as claimed. Response to Arguments Applicant argues that claim 1 remains open-ended, but incorporates a negative limitation into Step 1A which disallows BMP and Activin A. (Remarks, p7). Applicant argues that the medium of Ingber comprises these reagents and is therefore, materially different from the claimed invention. (Remarks, p7-8). Applicant’s arguments, see p7-8, with respect to claims 1-4, 6-7, 9, 11, and 14-16 specifically have been fully considered and are persuasive. Therefore, the rejection of claims 1-4, 6-7, 9, 11, and 14-16 under 35 USC 103 as being obvious over Ingber et al. (WO2016085765A1, on IDS 04/18/2024) in view of Ciampi et al. (Stem Cell Research, 2016, on IDS 04/18/2024) etc., has been withdrawn. However, Applicant should note that the specific exclusion of reagents such as BMP and Activin A is considered new matter. Specifically, these new limitations were not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Therefore, claims 1-4, 6-7, 9, 11, and 14-16 are rejected under 35 USC 112(a) as discussed above. Furthermore, it is noted that claims 8 and 12-13 do not require these new limitations and therefore, their rejection under 35 U.S.C. 103 as being unpatentable over Ingber et al. (WO2016085765A1, on IDS 04/18/2024) in view of Ciampi et al. (Stem Cell Research, 2016, on IDS 04/18/2024) is maintained as discussed above. Applicant also argues that the claimed Step S1 lacks a GSK-3 inhibitor (specifically, “Step S1 of the present application employs only modified RPMI 1640 supplemented with CHIR99021, and is defined to be free of Activin A and BMP, lacking the two key components present in D1 (Activin A+GSK inhibitor) or D2 (bmp4+GSK inhibitor)”). Continuing, Applicant argues that “Step S2 of the present application uses modified RPMI 1640 plus FGF9, BMP7 and vitamin A, and omits CHIR99021, VEGF and B27 disclosed in D1. Step S3 of the present application uses DMEM/F12 supplemented with FBS, L-glutamine, vitamin D3 and vitamin A. By contrast, D1 contains neither FBS nor vitamin D3, and additionally includes VEGF, Activin A, BMP7, and CHIR99021.” (Remarks, p8). It is noted that D1 refers to Ingber and D1 refers to Ciampi. Applicant’s arguments filed 08/31/2026 with respect to claims 1-4, 6-7, 9, 11, and 14-16 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. However, it is noted that it is unclear what Applicant’s argument refers to because Applicant appears to be arguing that the claimed step S1 is free of a GSK inhibitor. However, step S1 of independent claims 1 and 9 are explicitly limited to “using a [medium] containing a GSK-3α/β inhibitor.” Additionally, it is noted that Step S2 does not omit CHIR99021, VEGF, and B27, and Step S3 does not VEGF, Activin A, BMP7, and CHIR99021 as asserted by Applicant. Rather, S2 (of independent claim 1) is limited to a medium “containing” FGF9, BMP7 and vitamin A, while S3 (of independent claim 1) is a medium “containing” fetal bovine serum stabilized L-glutamine, vitamin D3, and vitamin A. Specifically, there is no indication in the disclosure that the transitional word “containing” is closed-ended (i.e. synonymous with “consisting”), according to MPEP 2111.03 the terms “containing” and “comprising” as synonymous (See, e.g., Mars Inc. v. H.J. Heinz Co., 377 F.3d 1369, 1376, 71 USPQ2d 1837, 1843 (Fed. Cir. 2004) (“[L]ike the term ‘comprising,’ the terms ‘containing’ and ‘mixture’ are open-ended.”), and moreover, Applicant admits that the term “containing” is open-ended (see Remarks, p7, 08/31/2026, “The amended Claim 1 remains open-ended “containing”). Therefore, in regards to Applicant’s arguments regarding the limitations of the claims generally, Applicant’s arguments filed 03/31/2026 have been fully considered but are not found persuasive. Continuing, Applicant argues that step S1 of claim 1 pluripotent stem cells are treated only with CHIR99021 without Activin A or BMP4, and in merely 3 days. (Remarks, p9). However, Applicant argues that Ingber obtains intermediate mesoderm with BMP7 and CHIR99021 in as long as 18 days and that Ciampi generates intermediate mesoderm with GSK-3 inhibitor CP21R7 with BMP4 for 3 days. (Remarks, p8-9). Applicant’s arguments filed 08/31/2026 with respect to claims 1-4, 6-7, 9, 11, and 14-16 (corresponding to Step S1) have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Regarding Ciampi specifically, Applicant argues that the reference adopts a three-stage culture protocol, its medium formulations diverge from the claimed media, and its technical framework centers on continuous, non-passaged differentiation. (Remarks, 9-10). In contrast, Applicant argues that the present application establishes nephron progenitor cells as an intermediate stage that can be cryopreserved and revived. (Remarks, p10). Applicant’s arguments filed 03/31/2026 have been fully considered but are not found persuasive. In response to Applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., cryopreserving and reviving steps) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Applicant also argues that a person of ordinary skill in the art could not have modified the method of Ingber with Ciampi with predicable results and a reasonable expectation of success. (Remarks, p10). As evidence, Applicant argues that “comparative example 3 of the present application reproduces the culture conditions of D2” (i.e., Ciampi), wherein nephron progenitor cells were treated for 8 days with medium containing fetal bovine serum, stabilized L-glutamine, vitamin D3 and retinoic acid (see paragraphs [0074]-[0082] of the instant specification). (Remarks, p10). As argued by Applicant, qPCR was performed to detect podocyte marker genes Nephrosis2, Synaptopodin and Nephrin, but the results showed that compared with induced pluripotent stem cells, there was no statistically significant difference observed for the expression of Nephrosis2 and Nephrin (P>0.05). (Remarks, p10). Applicant argues that while retinoic acid is a derivative of vitamin A, because they have distinct structural and biological differences, they cannot be considered equivalent substitutes. (Remarks, p10). Therefore, Applicant concludes that this demonstrates that a system employing retinoic acid cannot achieve sufficient differentiation of nephron progenitor cells into podocytes. (Remarks, p10). Applicant’s arguments filed 08/31/2026 have been fully considered but are not found persuasive. It is first noted that despite Applicant’s assertions regarding Comparative Example 3 of the specification and Ciampi, there is no indication in the disclosure that Comparative Example 3 reproduces Ciampi. Additionally, regarding differences in vitamin A and retinoic acid, Ingber specifically envisions the use of either vitamin A or retinoic acid for the preparation of podocytes from pluripotent stem cells. Specifically, while Ingber uses the term “retinoic acid” in the claims, Ingber explicitly teaches that this broadly refers to derivatives including retinol (vitamin A) (paragraph [00102], “Retinoic acid: Retinoic acid is a metabolite of vitamin A (retinol) that mediates the functions of vitamin A required for growth and development. As used herein and throughout the specification, the term "retinoic acid" generally refers to a naturally occurring retinoic acid or a derivative thereof . . . examples of retinoic acid and derivative thereof include, but are not limited to . . . retinol”; see Office Action 06/01/2026, p5). Furthermore, in regards to expression of markers Nephrosis2, Synaptopodin and Nephrin, the claims do not require expression of these markers, and although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Furthermore, Ingber explicitly teaches that the podocytes express markers synaptopodin, nephrin, and podocin (i.e., the protein produced by the Nephrosis2 (NPHS2) gene) (paragraph 00137]), and therefore, have the same property. Applicant also argues that the claimed invention achieves unexpected results. (Remarks, p10). Specifically, Applicant argues that as demonstrated in Example 1 of the specification, replacing retinoic acid with vitamin A, while keeping other conditions unchanged enables complete differentiation of nephron progenitors into mature podocytes accompanies by high expression of genes SYNPO and ITGB3 (citing Fig. 4). (Remarks, p10). Continuing, Applicant argues that under the precondition that no BMP4 is involved in the induction step S1, only the selection of vitamin A rather than retinoic acid in Step S3 can accomplish podocyte differentiation, an effect that cannot be derived from Ciampi. (Remarks, p10). Applicant’s arguments filed 08/31/2026 have been fully considered but are not found persuasive. As above, the claims do not require expression of SYNPO and ITGB3, and although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Furthermore, regarding the precondition that there is no BMP4 involved in the induction step S1, as discussed above, the generic recitation of step S1 lacking “BMP” is new matter as discussed above. Moreover, it is noted that a negative limitation against BMP4 specifically would also be considered new matter. Applicant argues that the claimed invention saves expenses by eliminating costly cytokines such as Activin A and BMP4. (Remarks, p10). Applicant’s arguments filed 08/31/2026 have been fully considered but are not found persuasive. This is an assertion without evidence. Furthermore, as discussed above, the negative limitations regarding Activin A and BMP (or BMP4 specifically) are new matter that lacks disclosure. Applicant argues that none of Morizane or Qian cures the deficiencies of Ingber or Ciampi. (Remarks, p11). Applicant’s arguments filed 08/31/2026 regarding claims 1-4, 6-7, 9, 11, and 14-16 (corresponding to Step S1) have been considered but are moot because the new ground of rejection does not rely on any reference (Ingber or Ciampi) applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. It is noted that the rejections of claims 8 and 12-13 under 35 USC 103 as being obvious over Ingber in view of Ciampi does not rely on Morizane or Qian and therefore, Applicant’s arguments are not germane to the rejection of these claims. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH (PAUL) MIANO whose telephone number is (571)272-0341. The examiner can normally be reached Mon-Fri from 8:30am to 5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James (Doug) Schultz can be reached at (571) 272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOSEPH PAUL MIANO/Examiner, Art Unit 1631 /JAMES D SCHULTZ/Supervisory Patent Examiner, Art Unit 1631
Read full office action

Prosecution Timeline

Apr 18, 2024
Application Filed
Jun 01, 2026
Non-Final Rejection mailed — §103, §112
Aug 31, 2026
Response Filed
Sep 18, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12709738
COMPOSITIONS AND METHODS FOR INCREASING THE CULTURE DENSITY OF A CELLULAR BIOMASS WITHIN A CULTIVATION INFRASTRUCTURE
3y 10m to grant Granted Aug 18, 2026
Patent 12674133
METHODS FOR SEX-SORTING SPERM
6y 3m to grant Granted Jul 07, 2026
Patent 12655388
VIRUS-LIKE PARTICLE
4y 5m to grant Granted Jun 16, 2026
Patent 12642792
CA2-IL15 FUSION PROTEINS FOR TUNABLE REGULATION
4y 2m to grant Granted Jun 02, 2026
Patent 12558381
DEVELOPMENT OF AMNION-LIKE TISSUE FROM HUMAN PLURIPOTENT STEM CELLS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
36%
Grant Probability
99%
With Interview (+63.4%)
4y 2m (~1y 8m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 112 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month